Ramy A Mahmoud

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. pmc Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study
    Frank D Gianfrancesco
    HECON Associates Inc, 9833 Whetstone Drive, Montgomery Village, MD 20886, USA
    Ann Gen Psychiatry 8:5. 2009
  2. ncbi request reprint Risperidone for treatment-refractory major depressive disorder: a randomized trial
    Ramy A Mahmoud
    Ortho McNeil Janssen Scientific Affairs, Titusville, New Jersey, USA
    Ann Intern Med 147:593-602. 2007
  3. doi request reprint Psychometric evaluation of a Patient-Rated Most Troubling Symptom Scale for Depression: findings from a secondary analysis of a clinical trial
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
    Int Clin Psychopharmacol 25:51-9. 2010
  4. ncbi request reprint Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
    Psychopharmacol Bull 40:41-57. 2007
  5. ncbi request reprint A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder
    George M Simpson
    Department of Psychiatry, Keck School of Medicine of the University of Southern California, Los Angeles, USA
    J Clin Psychiatry 67:1194-203. 2006
  6. ncbi request reprint Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study
    Philip D Harvey
    Department of Psychiatry, Mt Sinai School of Medicine, New York, NY, USA
    J Clin Psychiatry 68:1186-94. 2007
  7. ncbi request reprint Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Neuropsychopharmacology 31:2505-13. 2006
  8. ncbi request reprint Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam
    Glenn W Currier
    Departments of Psychiatry and Emergency Medicine, University of Rochester Medical Center, 300 Crittenden Boulevard, Rochester, N Y 14642, USA
    J Clin Psychiatry 65:386-94. 2004
  9. doi request reprint Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004)
    William DuMouchel
    Lincoln Technologies Inc, Waltham, Massachusetts, USA
    Ann Clin Psychiatry 20:21-31. 2008
  10. ncbi request reprint Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database
    Frank D Gianfrancesco
    HECON Associates, Montgomery Village, MD 20886, USA
    J Clin Psychiatry 63:920-30. 2002

Collaborators

Detail Information

Publications10

  1. pmc Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study
    Frank D Gianfrancesco
    HECON Associates Inc, 9833 Whetstone Drive, Montgomery Village, MD 20886, USA
    Ann Gen Psychiatry 8:5. 2009
    ..We assessed two potential explanations: disproportionately more prolactin assessment and head/brain imaging in risperidone-treated patients vs patients treated with other antipsychotics...
  2. ncbi request reprint Risperidone for treatment-refractory major depressive disorder: a randomized trial
    Ramy A Mahmoud
    Ortho McNeil Janssen Scientific Affairs, Titusville, New Jersey, USA
    Ann Intern Med 147:593-602. 2007
    ..Major depressive disorder has high prevalence, morbidity, and mortality. Inadequate results with antidepressants have prompts addition of a nonstandard treatment (augmentation therapy)...
  3. doi request reprint Psychometric evaluation of a Patient-Rated Most Troubling Symptom Scale for Depression: findings from a secondary analysis of a clinical trial
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
    Int Clin Psychopharmacol 25:51-9. 2010
    ..In conclusion, PaRTS-D may be useful in symptom presence and severity assessments from the patient's perspective and as an adjunctive to other instruments in major depressive disorder diagnosis and response to treatment...
  4. ncbi request reprint Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
    Psychopharmacol Bull 40:41-57. 2007
    ....
  5. ncbi request reprint A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder
    George M Simpson
    Department of Psychiatry, Keck School of Medicine of the University of Southern California, Los Angeles, USA
    J Clin Psychiatry 67:1194-203. 2006
    ..This study examined the effects of 2 doses of long-acting risperidone injection in patients with schizophrenia or schizoaffective disorder...
  6. ncbi request reprint Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study
    Philip D Harvey
    Department of Psychiatry, Mt Sinai School of Medicine, New York, NY, USA
    J Clin Psychiatry 68:1186-94. 2007
    ..The primary objective of this double-blind study was to compare the effects of treatment initiation with risperidone and quetiapine on cognitive function in subjects with stable bipolar disorder...
  7. ncbi request reprint Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Neuropsychopharmacology 31:2505-13. 2006
    ..1 and 64.1%, respectively (p < or = 0.05). Open-label risperidone augmentation substantially enhanced response in treatment-resistant patients, but the longer-term benefits of augmentation were not demonstrated in this study...
  8. ncbi request reprint Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam
    Glenn W Currier
    Departments of Psychiatry and Emergency Medicine, University of Rochester Medical Center, 300 Crittenden Boulevard, Rochester, N Y 14642, USA
    J Clin Psychiatry 65:386-94. 2004
    ..We hypothesized that the efficacy and speed of action of both treatments would be similar...
  9. doi request reprint Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004)
    William DuMouchel
    Lincoln Technologies Inc, Waltham, Massachusetts, USA
    Ann Clin Psychiatry 20:21-31. 2008
    ..This analysis compared diabetes-related adverse events associated with use of different antipsychotic agents. A disproportionality analysis of the US Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) was performed...
  10. ncbi request reprint Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database
    Frank D Gianfrancesco
    HECON Associates, Montgomery Village, MD 20886, USA
    J Clin Psychiatry 63:920-30. 2002
    ..Case series suggest that some antipsychotics may induce or exacerbate type 2 diabetes. This study measured the association of antipsychotic treatments with diabetes at a population level...